title: [Treatment strategy of osteoporosis after the bisphosphonates discontinuation.]
abstract: Cases discontinuing bisphosphonates(BPs)include cases due to adverse effects, non adherence, no effectiveness, and lower risk of fragile fractures. For patients with osteonecrosis of the jaw or atypical femoral fracture, discontinuation of BPs and the switch to Teriparatides may be recommended until the treatments are completed. For the patients of discontinuation of BPs due to lower risk of fractures, the treatment strategy will be determined based on the presence or absence of fracture, the change of bone mineral density and bone resorption markers.
authors.affiliation: Department of Orthopaedic Surgery and Rheumatology, Kindai University Nara Hospital, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Soen
mesh_terms: D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D050723:Fractures, Bone / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates